Interpace Biosciences Inc (IDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 9,032 | 9,225 | 8,756 | 9,232 | 11,515 |
| Cost of Goods | 3,128 | 3,180 | 3,317 | 3,956 | 4,145 |
| Gross Profit | 5,904 | 6,045 | 5,439 | 5,276 | 7,370 |
| Operating Expenses | 4,909 | 4,647 | 4,611 | 6,700 | 5,686 |
| Operating Income | 1,123 | 1,578 | 1,145 | -468 | 1,829 |
| Other Income | 10 | -43 | -145 | -65 | -57 |
| Pre-tax Income | 1,133 | 1,535 | 1,000 | -533 | 1,772 |
| Income Tax | 302 | -21,217 | -11 | N/A | 18 |
| Net Income Continuous | 831 | 22,752 | 1,011 | -533 | 1,754 |
| Net Income Discontinuous | -110 | -95 | -100 | -107 | -107 |
| Net Income | $721 | $22,657 | $911 | $-640 | $1,647 |
| EPS Basic Total Ops | 0.03 | 5.11 | 0.21 | -0.14 | 0.37 |
| EPS Basic Continuous Ops | 0.04 | 5.14 | 0.23 | -0.12 | 0.40 |
| EPS Basic Discontinuous Ops | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 |
| EPS Diluted Total Ops | 0.03 | 0.94 | 0.03 | -0.14 | 0.06 |
| EPS Diluted Continuous Ops | 0.03 | 0.92 | 0.04 | -0.12 | 0.06 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.02 | -0.01 | -0.02 | 0.00 |
| EPS Diluted Before Non-Recurring Items | 0.03 | N/A | 0.04 | -0.12 | 0.06 |
| EBITDA(a) | $1,348 | $1,815 | $1,372 | $-254 | $2,030 |